Slides
Page 1
14 January 2025 Pioneering access for patients Richard Saynor, CEO
Page 2
2 This presentation contains forward‐looking statements that reflect the current views of management, which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Sandoz to differ materially from those expressed or implied in this presentation. Statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Sandoz is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities. This presentation includes non-IFRS financial measures as defined by Sandoz. An explanation of non-IFRS measures can be found in the Supplementary financial information of the Half-Year Report 2024. Disclaimer position in an attractive market
Page 3
3 1. This is Sandoz 2. Delivering on our promises 3. Capturing long-term opportunities Agendan in an attractive market
Page 4
This is Sandoz
Page 5
> USD 200 billion Market size1 Growing at 7%1,2 with increasing share of biosimilars USD 9.6 billion FY 2023 net sales3 Double-digit growth in biosimilars All regions contributing to growth Top 3 player In 90% of European markets4 European champion present in over 40 markets 80% Pipeline coverage in generics Opportunities remaining strong beyond 2028 in generics GLP-1s key opportunity in 2026+ #1 In biosimilars worldwide 28 biosimilars in development Successful new launches of Hyrimoz® in the US as well as Tyruko® and Pyzchiva® in Europe <2.0x Net debt to core EBITDA ratio Strong balance sheet supporting near-term capital investments 1. Based on company analysis using IQVIA Analytics Link MAT12- 2023 data in LCUSD at gross price, excl. certain sizeable markets with no or limited Sandoz operations 2. 2023-2032 CAGR for Biocomparable, Early Entry Generics and Generics as defined by IQVIA and includes all ATC and NFC forms 4. IQVIA MIDAS MAT09-2024 for 18 markets in Europe5 1Leading position in an attractive market 3. Net sales to third parties